CINJ Pancreatic Tumor Vaccine Awarded High-Rated Distinction

According to the American Cancer Society, Pancreatic Cancer is the fourth-leading cause of cancer death in the nation and is expected to take 37,400 lives this year. However, there has been some progress in the treatment of pancreatic cancer at The Cancer Institute of New Jersey (CINJ), according to a news article on NJ.com.

Researchers at CINJ in New Brunswick, New Jersey have made progress in treatment including the injection of a virus-vaccine directly into the tumor. The American Association for Cancer Research has awarded this treatment a high distinction for work in progress. The findings up until now have been promising, and demonstrate a strengthening of the immune system.

The development of new and more effective treatment is important in combating deadly diseases, but these treatments may be ineffective if a healthcare professional fails to diagnose the disease in a timely manner or misdiagnoses the disease. A patient’s positive prognosis is directly linked to accurate and timely diagnosis, timely and correct treatment, as well as the effectiveness of treatment. If a healthcare professional fails to diagnose or misdiagnoses pancreatic cancer, then the fact that there are new effective methods of treating/managing the disease is inconsequential.

At Blume Forte, our New Jersey pancreatic cancer misdiagnosis attorneys experience in handling complex claims concerning failures in the diagnosis and treatment of cancer, and other types of medical negligence. To find out whether you may have a meritorious claim, contact our offices for a no-cost consultation at (973) 635-5400.

Related Articles: